Lunit has raised $61.0M in total across 1 funding round.
Lunit's investors include A7V, Alpine Ventures, Goodwater Capital, HealthQuest Capital, NextGen Venture Partners, Ontario Teachers' Pension Plan.
Lunit is a Seoul-based medical AI company developing software for cancer screening, diagnostics, and precision oncology using deep learning technology.[1][2][3] Its core products include AI solutions for analyzing medical images like chest X-rays, mammograms, and digital breast tomosynthesis, as well as biomarkers for immunotherapy, serving over 10,000 sites in 65+ countries including partnerships with GE Healthcare, Fujifilm, Philips, and Guardant Health.[1][3][4][5] Lunit addresses radiologist shortages and diagnostic inconsistencies by transforming complex imaging, pathology, and biomarker data into actionable insights, improving early detection and treatment decisions for healthcare providers and patients worldwide.[3][5] The company has shown strong growth momentum, with Q1 revenue reaching 19.2 billion won (up 274% year-on-year), driven largely by overseas sales in regions like the Middle East.[2]
Founded in 2013 in Seoul, South Korea, Lunit emerged as a first-generation medical AI pioneer, backed by investors like SoftBank.[2][6] The company's idea stemmed from leveraging cutting-edge deep learning to tackle inefficiencies in cancer diagnostics, particularly in imaging analysis where human error and workload pressures limit accuracy.[1][5] Early traction came from developing AI for chest X-rays and mammography, leading to FDA clearance, CE marking under MDR, and rapid global adoption at over 1,000 medical sites initially, expanding to 10,000+ today through partnerships with healthcare leaders.[1][5] Pivotal moments include filing 92 patents in machine learning and neural networks, and achieving record revenues, solidifying its position as a public company on KOSDAQ (328130).[2][7]
Lunit stands out in the medical AI space through these key strengths:
Lunit rides the wave of AI in precision oncology, capitalizing on surging demand for tools that address global radiologist shortages and rising cancer burdens amid aging populations.[1][5] Timing is ideal as regulatory approvals (FDA, CE) align with healthcare's post-pandemic push for digital transformation, while multimodal data integration positions it ahead of fragmented competitors like Qure.ai or Aidoc.[2][5] Market forces favoring Lunit include explosive growth in medical imaging AI (projected multi-billion market), overseas expansion (93% of recent revenue), and biopharma needs for AI biomarkers in immunotherapy trials.[2][4] It influences the ecosystem by setting standards for interoperable, validated AI, partnering with OEMs to embed solutions in workflows, and advancing foundation models for scalable cancer care innovation.[3][5]
Lunit is poised for accelerated global dominance in cancer AI, with next steps focusing on next-generation foundation models, strategic acquisitions, and deeper biopharma integrations for companion diagnostics.[3][5] Trends like multimodal AI, regulatory harmonization, and AI-driven trials will propel its growth, potentially boosting revenues further as adoption hits emerging markets and U.S./Europe scales.[2][4] Its influence may evolve from diagnostic enhancer to oncology platform leader, redefining precision care much like it began—by turning data into life-changing decisions for clinicians and patients.[1][3]
Lunit has raised $61.0M across 1 funding round. Most recently, it raised $61.0M Venture Round in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $61.0M Venture Round | A7V, Alpine Ventures, Goodwater Capital, HealthQuest Capital, NextGen Venture Partners, Ontario Teachers' Pension Plan |
